Synofzik, Matthis http://orcid.org/0000-0002-2280-7273
Helbig, Katherine L.
Harmuth, Florian
Deconinck, Tine
Tanpaiboon, Pranoot
Sun, Bo
Guo, Wenting
Wang, Ruiwu
Palmaer, Erika
Tang, Sha
Schaefer, G. Bradley
Gburek-Augustat, Janina
Züchner, Stephan
Krägeloh-Mann, Ingeborg
Baets, Jonathan
de Jonghe, Peter
Bauer, Peter
Chen, S. R. Wayne
Schöls, Ludger
Schüle, Rebecca
Funding for this research was provided by:
EU E-RARE JTC grant “PREPARE”
Senior Clinical Researcher mandate of the Research Fund - Flanders
the Canadian Institutes of Health Research (CIHR), the Canada Foundation for Innovation (CFI), and the Heart and Stroke Foundation Chair in Cardiovascular Research
Article History
Received: 9 September 2017
Revised: 26 March 2018
Accepted: 5 June 2018
First Online: 20 June 2018
Compliance with ethical standards
:
: MS received consulting fees from Actelion Pharmaceuticals Ltd. KLH, EP and ST are employed by Ambry Genetics. IK-M received consulting fees from Actelion Pharmaceuticals Ltd. PB is Chief Operating Officer at Centogene AG, Rostock, since January 2016. This company has no direct market-related interests in this study and was not involved in any parts of this study. The other authors declare that they have no conflict of interest.